Clinical Trials Browser

Phase 1 × AVE9633 × Clear all

NCT00543972 2009-05-14

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid